Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
J.Molner ASOTSE:MOLNR -0.53%40 PB Ratio is 15.07 as of Aug. 31, 2026, which is 66% below its 10-year median of 44.81. GuruFocus rates OTSE:MOLNR with a GF Score™ of 40/100 and a GF Value™ of €19.62 (Fairly Valued). The stock has 7 warning signs investors should review. Among 920 Drug Manufacturers companies, J.Molner AS ranks worse than 94.89% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-31), J.Molner AS's share price is €18.90. J.Molner AS's Book Value per Share for the quarter that ended in Dec. 2025 was €1.25. Hence, J.Molner AS's PB Ratio of today is 15.07.
Good Sign:
J.Molner AS stock PB Ratio (=15.07) is close to 5-year low of 15.07.
The historical rank and industry rank for J.Molner AS's PB Ratio or its related term are showing as below:
OTSE:MOLNR'
s PB Ratio Range Over the Past 10 Years
Min: 15.07 Med: 44.81 Max: 83.84
Current: 15.07
During the past 5 years, J.Molner AS's highest PB Ratio was 83.84. The lowest was 15.07. And the median was 44.81.
OTSE:MOLNR's PB Ratio is ranked worse than 94.89% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.98
vs OTSE:MOLNR: 15.07
During the past 12 months, J.Molner AS's average Book Value Per Share Growth Rate was 128.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 97.00% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of J.Molner AS was 97.00% per year. The lowest was 97.00% per year. And the median was 97.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
J.Molner AS PB Ratio Related Terms
J.Molner AS PB Ratio Historical Data
* Premium members only.
The historical data trend for J.Molner AS's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OTSE:MOLNR vs ZTS, UTHR, VTRS: PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, J.Molner AS's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
J.Molner AS PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, J.Molner AS's PB Ratio distribution charts can be found below:
* The bar in red indicates where J.Molner AS's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
J.Molner AS's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
J.Molner AS (OTSE:MOLNR) has a PB Ratio of 15.07 as of Aug. 31, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on J.Molner AS and its competitors. This is 66% below median its historical median of 44.81. Over the past decade, J.Molner AS's PB Ratio has ranged from 15.07 to 83.84. According to the industry distribution chart, J.Molner AS ranks #873 out of 920 companies in the Drug Manufacturers industry, placing it in the top 94.9%.
Is J.Molner AS's PB Ratio too high?
J.Molner AS's current PB Ratio of 15.07 is 66% below median its 10-year median of 44.81. Over the past 10 years, this metric has ranged from a low of 15.07 to a high of 83.84. The Drug Manufacturers industry median PB Ratio is 1.98. J.Molner AS's value of 15.07 is 661.1% above this industry median. Based on the distribution chart, J.Molner AS ranks #873 out of 920 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, J.Molner AS has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does J.Molner AS's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, J.Molner AS ranks #873 out of 920 companies for PB Ratio. This places J.Molner AS in the lower half of its industry. The industry median PB Ratio is 1.98. J.Molner AS's value of 15.07 is 661.1% above this benchmark. Historically, J.Molner AS's own PB Ratio has ranged from 15.07 to 83.84 over the past decade. While the company's 10-year median is 44.81 vs. the industry median of 1.98, J.Molner AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.98, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. J.Molner AS's current PB Ratio of 15.07 is 661.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on J.Molner AS and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. J.Molner AS's current PB Ratio is 15.07, which is 66% below median its own 10-year median of 44.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J.Molner AS stock overvalued right now?
Based on GuruFocus' analysis, J.Molner AS (OTSE:MOLNR) is currently considered Fairly Valued. The stock's GF Value™ is €19.62, compared to a current price of €18.90 — trading 3.7% below its estimated fair value. The current PB Ratio is 15.07, which is 66% below median its 10-year median of 44.81 and 661.1% above the Drug Manufacturers industry median of 1.98. J.Molner AS's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For J.Molner AS (OTSE:MOLNR), the current PB Ratio is 15.07 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is J.Molner AS (OTSE:MOLNR) Overvalued in 2026?
Based on GuruFocus' analysis, J.Molner AS stock appears to be undervalued.
The current stock price of €18.90 is trading 3.7% below its estimated GF Value™ of €19.62.
GuruFocus considers J.Molner AS to be Fairly Valued.
Key valuation signals for OTSE:MOLNR:
PB Ratio: 15.07 (66% below median its 10-year median of 44.81)
GF Value™: €19.62 vs. price of €18.90 (3.7% below fair value)
Industry Position: 661.1% above the Drug Manufacturers median (#873 of 920)
No single metric tells the full story. See the OTSE:MOLNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
J.Molner AS is an Estonia-based company engaged in research and development in the field of biotechnology. It is developing a portfolio of generic drug products for the United States and Canadian markets, consisting of both in-house developed medicines and acquired and in-licensed products. It operates through two complementary business units: internal generic drug development and specialized pharmaceutical services. It develops and commercializes sterile injectable, ophthalmic, and dermatology generic drugs, while also providing drug development services, analytical chemistry and stability testing. Its activities are divided into two business segments, Generic Drugs and Services, with Services generating maximum revenue. The Company generates maximum revenue from the United States.
40GF Score
Get the complete analysis for OTSE:MOLNR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTSE:MOLNR has been successfully added to your 
